Targeting Mutated Epidermal Growth Factor Receptor
Final rept. 1 Jul 1996-30 Jun 2001
WISTAR INST OF ANATOMY AND BIOLOGY PHILADELPHIA PA
Pagination or Media Count:
During this four-year funding and one-year no cost extension periods we have established a rat model of active specific immunotherapy against mutated epidermal growth factor receptor EGF-RvIII specifically expressed by breast carcinomas. The mutation is not expressed by normal breast tissues. The model system consists of rat mammary carcinomas expressing EGF-RvIII after cDNA transfer and EGF-RvIII vaccines, including recombinant EGF-RvIII protein, EGF-RvIII expressed in adenovirus vector and peptides mimicking EGF-RvIII. Expression of EGF-RvIII by the transfected rat mammary carcinoma cells was instable due to vector mutations. The vector was corrected but rat mammary carcinoma cells transfected with the vector did not stably express EGF-RvIII. Future studies will be aimed at obtaining stable transfectants. These will allow us to test the available vaccines for their tumor growth inhibiting properties. We have also evaluated breast cancer patients immune responses to EGF-RvIII. Most patients with EGF-RvIII-positive lesions had circulating antibodies, and a few patients also EGF-RvIII specific lymphoproliferative responses. These responses may be beneficial to the patients, and this issue will be addressed in future studies in a larger population of patients.
- Anatomy and Physiology
- Medicine and Medical Research